Ribonucleotide reductase as one important target of [Tris(1,10- phenanthroline)lanthanum(III)] trithiocyanate (KP772)

Current Cancer Drug Targets

Volumn 9, Issue 5, 2009, Pages 595-607

  Heffeter, P ^a   Popovic Bijelic, A ^b   Saiko, P ^c   Dornetshuber, R ^d   Jungwirth, U ^a   Voevodskaya, N ^b   Biglino, D ^e   Jakupec, M A ^d   Elbling, L ^a   Micksche, M ^a   Szekeres, T ^c   Keppler, B K ^d   Graslund A ^b   Berger, W ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b STOCKHOLM UNIVERSITY   (Sweden)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF VIENNA   (Austria)

^e JO EF STEFAN INSTITUTE   (Slovenia)

Author keywords

1,10 phenanthroline; Anticancer activity; Cell cycle arrest; KP772; Lanthanum; Ribonucleotide reductase

Indexed keywords

[TRIS(1,10 PHENANTHROLINE)LANTHANUM]TRITHIOCYANATE; ANTINEOPLASTIC AGENT; CYTIDINE; DEOXYNUCLEOSIDE TRIPHOSPHATE; FERROUS ION; IRON COMPLEX; KP 772; LANTHANUM; NUCLEOSIDE DERIVATIVE; PHENANTHROLINE DERIVATIVE; PROTEIN P53; RIBONUCLEOTIDE REDUCTASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; COMPLEX FORMATION; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; CYTOSTASIS; DNA SYNTHESIS INHIBITION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; ELECTRON SPIN RESONANCE; ENZYME INHIBITION; ENZYME SUBUNIT; HOMEOSTASIS; HUMAN; HUMAN CELL; IRON CHELATION; MOLECULAR INTERACTION; MOUSE; NONHUMAN; OXIDATIVE STRESS;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DINUCLEOSIDE PHOSPHATES; DNA; DRUG SYNERGISM; FEMALE; HUMANS; HYDROXYUREA; IRON; IRON CHELATING AGENTS; NUCLEOTIDES; ORGANOMETALLIC COMPOUNDS; PHENANTHROLINES; REACTIVE OXYGEN SPECIES; RECEPTORS, TRANSFERRIN; RIBONUCLEOTIDE REDUCTASES;

EID: 69249221512     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800909789056962     Document Type: Article

References (55)

1. Heffeter, P.; Jakupec, M. A.; Korner, W.; Wild, S.; von Keyserlingk, N. G.; Elbling, L.; Zorbas, H.; Korynevska, A.; Knasmuller, S.; Sutterluty, H.; Micksche, M.; Keppler, B. K.; Berger, W. Anticancer activity of the lanthanum compound [tris(1,10-phenanthroline)lanthanum(III)]trithiocyanate (KP772; FFC24). Biochem. Pharmacol. 2006, 71, 426-440. (Pubitemid 43077077)
2. Heffeter, P.; Jakupec, M. A.; Korner, W.; Chiba, P.; Pirker, C.; Dornetshuber, R.; Elbling, L.; Sutterluty, H.; Micksche, M.; Keppler, B. K.; Berger, W. Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24). Biochem. Pharmacol. 2007, 73, 1873-1886. (Pubitemid 46677901)
3. Tsimberidou, A. M.; Alvarado, Y.; Giles, F. J. Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies. Expert Rev. Anticancer Ther. 2002, 2, 437-448. (Pubitemid 34947120)
4. Hatse, S.; De Clercq, E.; Balzarini, J. Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation. Biochem. Pharmacol. 1999, 58, 539-555. (Pubitemid 29296875)
5. Shao, J.; Zhou, B.; Chu, B.; Yen, Y. Ribonucleotide reductase inhibitors and future drug design. Curr Cancer Drug Targets 2006, 6, 409-431. (Pubitemid 44033390)
6. Kolberg, M.; Strand, K. R.; Graff, P.; Andersson, K. K. Structure, function, and mechanism of ribonucleotide reductases. Biochim. Biophys. Acta 2004, 1699, 1-34.
7. Bourdon, A.; Minai, L.; Serre, V.; Jais, J. P.; Sarzi, E.; Aubert, S.; Chretien, D.; de Lonlay, P.; Paquis-Flucklinger, V.; Arakawa, H.; Nakamura, Y.; Munnich, A.; Rotig, A. Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. Nat. Genet. 2007, 39, 776-780. (Pubitemid 46848590)
8. Green, D. A.; Antholine, W. E.; Wong, S. J.; Richardson, D. R.; Chitambar, C. R. Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: effect on the R2 subunit of ribonucleotide reductase. Clin. Cancer Res. 2001, 7, 3574-3579.
9. Sun, Y.; Bian, J.; Wang, Y.; Jacobs, C. Activation of p53 transcriptional activity by 1,10-phenanthroline, a metal chelator and redox sensitive compound. Oncogene 1997, 14, 385-393. (Pubitemid 27087101)
10. Nyholm, S.; Thelander, L.; Graslund, A. Reduction and loss of the iron center in the reaction of the small subunit of mouse ribonucleotide reductase with hydroxyurea. Biochemistry 1993, 32, 11569-11574.
11. Chou, T. C.; Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22, 27-55.
12. Szekeres, T.; Gharehbaghi, K.; Fritzer, M.; Woody, M.; Srivastava, A.; van't Riet, B.; Jayaram, H. N.; Elford, H. L. Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase. Cancer Chemother. Pharmacol. 1994, 34, 63-66.
13. Garrett, C.; Santi, D. V. A rapid and sensitive high pressure liquid chromatography assay for deoxyribonucleoside triphosphates in cell extracts. Anal. Biochem. 1979, 99, 268-273.
14. Heffeter, P.; Pongratz, M.; Steiner, E.; Chiba, P.; Jakupec, M. A.; Elbling, L.; Marian, B.; Korner, W.; Sevelda, F.; Micksche, M.; Keppler, B. K.; Berger, W. Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 [indazolium trans-[tetrachlorobis(1H-indazole) ruthenate (III)](FFC14A). J. Pharmacol. Exp. Ther. 2005, 312, 281-289.
15. Mann, G. J.; Graslund, A.; Ochiai, E.; Ingemarson, R.; Thelander, L. Purification and characterization of recombinant mouse and her pes simplex virus ribonucleotide reductase R2 subunit. Biochemistry 1991, 30, 1939-1947.
16. Yen, Y.; Grill, S. P.; Dutschman, G. E.; Chang, C. N.; Zhou, B. S.; Cheng, Y. C. Characterization of a hydroxyurea-resistant human KB cell line with supersensitivity to 6-thioguanine. Cancer Res. 1994, 54, 3686-3691. (Pubitemid 24241179)
17. Ask, A.; Persson, L.; Rehnholm, A.; Frostesjo, L.; Holm, I.; Heby, O. Development of resistance to hydroxyurea during treatment of human myelogenous leukemia K562 cells with alpha-difluoromethylornithine as a result of coamplification of genes for ornithine decarboxylase and ribonucleotide reductase R2 subunit. Cancer Res. 1993, 53, 5262-5268. (Pubitemid 23333397)
18. Flanagan, S. A.; Robinson, B. W.; Krokosky, C. M.; Shewach, D. S. Mismatched nucleotides as the lesions responsible for radiosensitization with gemcitabine: a new paradigm for antimetabolite radiosensitizers. Mol. Cancer Ther. 2007, 6, 1858-1868.
19. Lembo, D.; Donalisio, M.; Cornaglia, M.; Azzimonti, B.; Demurtas, A.; Landolfo, S. Effect of high-risk human papillomavirus oncoproteins on p53R2 gene expression after DNA damage. Virus Res. 2006, 122, 189-193. (Pubitemid 44634832)
20. Smardova, J.; Pavlova, S.; Svitakova, M.; Grochova, D.; Ravcukova, B. Analysis of p53 status in human cell lines using a functional assay in yeast: detection of new non-sense p53 mutation in codon 124. Oncol. Rep. 2005, 14, 901-907.
21. Zhu, C.; Johansson, M.; Karlsson, A. The subcellular location of nucleoside analog phosphorylation is a determinant of synergistic effects of hydroxyurea. Biochem. Biophys. Res. Commun. 2000, 276, 179-182.
22. Myette, M. S.; Elford, H. L.; Chitambar, C. R. Interaction of gallium nitrate with other inhibitors of ribonucleotide reductase: effects on the proliferation of human leukemic cells. Cancer Lett. 1998, 129, 199-204.
23. Tanaka, M.; Kimura, K.; Yoshida, S. Mechanism of synergistic cell killing by hydroxyurea and cytosine arabinoside. Jpn. J. Cancer Res. 1985, 76, 729-735. (Pubitemid 15232457)
24. Walsh, C. T.; Craig, R. W.; Agarwal, R. P. Increased activation of 1-beta-D-arabinofuranosylcytosine by hydroxyurea in L1210 cells. Cancer Res. 1980, 40, 3286-3292.
25. Karp, J. E.; Giles, F. J.; Gojo, I.; Morris, L.; Greer, J.; Johnson, B.; Thein, M.; Sznol, M.; Low, J. A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders. Leuk. Res. 2008, 32, 71-77. (Pubitemid 350100849)
26. Horvath, Z.; Saiko, P.; Illmer, C.; Madlener, S.; Hoechtl, T.; Bauer, W.; Erker, T.; Jaeger, W.; Fritzer-Szekeres, M.; Szekeres, T. Synergistic action of resveratrol, an ingredient of wine, with Ara-C and tiazofurin in HL-60 human promyelocytic leukemia cells. Exp. Hematol. 2005, 33, 329-335. (Pubitemid 40261314)
27. Kayyali, R.; Pannala, A. S.; Khodr, H.; Hider, R. C. Comparative radical scavenging ability of bidentate iron (III) chelators. Biochem. Pharmacol. 1998, 55, 1327-1332.
28. Kanno, S.; Kakuta, M.; Kitajima, Y.; Osanai, Y.; Kurauchi, K.; Ohtake, T.; Ujibe, M.; Uwai, K.; Takeshita, M.; Ishikawa, M. Preventive effect of trimidox on oxidative stress in U937 cell line. Biol. Pharm. Bull. 2007, 30, 994-998. (Pubitemid 46708638)
29. Aisen, P.; Enns, C.; Wessling-Resnick, M. Chemistry and biology of eukaryotic iron metabolism. Int. J. Biochem. Cell Biol. 2001, 33, 940-959.
30. Chua, A. C.; Graham, R. M.; Trinder, D.; Olynyk, J. K. The regulation of cellular iron metabolism. Crit. Rev. Clin. Lab. Sci. 2007, 44, 413-459.
31. Hoyer, G. Absorption-photometric determination of serum iron with 1,10-phenanthroline. Scand. J. Clin. Lab. Invest. 1950, 2, 125-132.
32. Chaston, T. B.; Lovejoy, D. B.; Watts, R. N.; Richardson, D. R. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin. Cancer Res. 2003, 9, 402-414.
33. Cerqueira, N. M.; Pereira, S.; Fernandes, P. A.; Ramos, M. J. Overview of ribonucleotide reductase inhibitors: an appealing target in anti-tumour therapy. Curr. Med. Chem. 2005, 12, 1283-1294.
34. Xie, K. C.; Plunkett, W. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl) adenine. Cancer Res. 1996, 56, 3030-3037. (Pubitemid 26200765)
35. Heinemann, V.; Xu, Y. Z.; Chubb, S.; Sen, A.; Hertel, L. W.; Grindey, G. B.; Plunkett, W. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol. Pharmacol. 1990, 38, 567-572. (Pubitemid 20356209)
36. Fox, R. M. Changes in deoxynucleoside triphosphate pools induced by inhibitors and modulators of ribonucleotide reductase. Pharmacol. Ther. 1985, 30, 31-42.
37. Roy, B.; Guittet, O.; Beuneu, C.; Lemaire, G.; Lepoivre, M. Depletion of deoxyribonucleoside triphosphate pools in tumor cells by nitric oxide. Free Radic. Biol. Med. 2004, 36, 507-516. (Pubitemid 38224521)
38. Gandhi, V.; Plunkett, W.; Kantarjian, H.; Talpaz, M.; Robertson, L. E.; O'Brien, S. Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia. J. Clin. Oncol. 1998, 16, 2321-2331. (Pubitemid 28309023)
39. Horvath, Z.; Murias, M.; Saiko, P.; Erker, T.; Handler, N.; Madlener, S.; Jaeger, W.; Grusch, M.; Fritzer-Szekeres, M.; Krupitza, G.; Szekeres, T. Cytotoxic and biochemical effects of 3,3′,4,4′,5,5′- hexahydroxystilbene, a novel resveratrol analog in HL-60 human promyelocytic leukemia cells. Exp. Hematol. 2006, 34, 1377-1384. (Pubitemid 44374836)
40. Giles, F. J.; Fracasso, P. M.; Kantarjian, H. M.; Cortes, J. E.; Brown, R. A.; Verstovsek, S.; Alvarado, Y.; Thomas, D. A.; Faderl, S.; Garcia-Manero, G.; Wright, L. P.; Samson, T.; Cahill, A.; Lambert, P.; Plunkett, W.; Sznol, M.; DiPersio, J. F.; Gandhi, V. Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk. Res. 2003, 27, 1077-1083.
41. Yu, T. W.; Anderson, D. Reactive oxygen species-induced DNA damage and its modification: a chemical investigation. Mutat. Res. 1997, 379, 201-210. (Pubitemid 27450540)
42. Licht, S.; Gerfen, G. J.; Stubbe, J. Thiyl radicals in ribonucleotide reductases. Science 1996, 271, 477-481.
43. Jiang, R.; Zhang, J. L.; Satoh, Y.; Sairenji, T. Mechanism for induction of hydroxyurea resistance and loss of latent EBV genome in hydroxyurea-treated Burkitt's lymphoma cell line Raji. J. Med. Virol. 2004, 73, 589-595. (Pubitemid 38857210)
44. Wong, S. J.; Myette, M. S.; Wereley, J. P.; Chitambar, C. R. Increased sensitivity of hydroxyurea-resistant leukemic cells to gemcitabine. Clin. Cancer Res. 1999, 5, 439-443. (Pubitemid 29085199)
45. Carter, G. L.; Cory, J. G. Cross-resistance patterns in hydroxyurea-resistant leukemia L1210 cells. Cancer Res. 1988, 48, 5796-5799.
46. Bergman, A. M.; Eijk, P. P.; Ruiz van Haperen, V. W.; Smid, K.; Veerman, G.; Hubeek, I.; van den Ijssel, P.; Ylstra, B.; Peters, G. J. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res. 2005, 65, 9510-9516. (Pubitemid 41508021)
47. Kramer, O. H.; Knauer, S. K.; Zimmermann, D.; Stauber, R. H.; Heinzel, T. Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis. Oncogene 2008, 27, 732-740. (Pubitemid 351186315)
48. Mukherji, A.; Janbandhu, V. C.; Kumar, V. GSK-3beta-dependent destabilization of cyclin D1 mediates replicational stress-induced arrest of cell cycle. FEBS Lett. 2008, 582, 1111-1116.
49. Hakansson, P.; Hofer, A.; Thelander, L. Regulation of mammalian ribonucleotide reduction and dNTP pools after DNA damage and in resting cells. J. Biol. Chem. 2006, 281, 7834-7841. (Pubitemid 43847398)
50. Pontarin, G.; Fijolek, A.; Pizzo, P.; Ferraro, P.; Rampazzo, C.; Pozzan, T.; Thelander, L.; Reichard, P. A.; Bianchi, V. Ribonucleotide reduction is a cytosolic process in mammalian cells independently of DNA damage. Proc. Natl. Acad. Sci. USA 2008, 105, 17801-17806.
51. Tanaka, T.; Huang, X.; Halicka, H. D.; Zhao, H.; Traganos, F.; Albino, A. P.; Dai, W.; Darzynkiewicz, Z. Cytometry of ATM activation and histone H2AX phosphorylation to estimate extent of DNA damage induced by exogenous agents. Cytometry A 2007, 71, 648-661. (Pubitemid 47351228)
52. Yang, J.; Wong, R. N.; Yang, M. S. Protective mechanism of metallothionein against copper-1, 10-phenanthroline induced DNA cleavage. Chem. Biol. Interact. 2000, 125, 221-232.
53. Cai, X.; Pan, N.; Zou, G. Copper-1,10-phenanthroline-induced apoptosis in liver carcinoma Bel-7402 cells associates with copper overload, reactive oxygen species production, glutathione depletion and oxidative DNA damage. Biometals 2007, 20, 1-11.
54. Shomron, N.; Malca, H.; Vig, I.; Ast, G. Reversible inhibition of the second step of splicing suggests a possible role of zinc in the second step of splicing. Nucleic Acids Res. 2002, 30, 4127-4137. (Pubitemid 35175181)
55. McCann, M.; Geraghty, M.; Devereux, M.; O'Shea, D.; Mason, J.; O'Sullivan, L. Insights into the mode of action of the anti-Candida activity of 1,10-phenanthroline and its metal chelates. Met. Based Drugs 2000, 7, 185-193. (Pubitemid 32015735)